TANRIVERDİ, L. H. And SARICI, A. 2024. CLL-247 Venetoclax Plus Ibrutinib As First-line Treatment in Patients With Chronic Lymphocytic Leukemia: Meta-Analysis of Randomised Controlled Trials. Society of Hematologic Oncology 2024 Annual Meeting , (Texas, United States Of America), 349.

TANRIVERDİ, L. H., & SARICI, A., (2024). CLL-247 Venetoclax Plus Ibrutinib As First-line Treatment in Patients With Chronic Lymphocytic Leukemia: Meta-Analysis of Randomised Controlled Trials . Society of Hematologic Oncology 2024 Annual Meeting (pp.349). Texas, United States Of America

TANRIVERDİ, LOKMAN, And AHMET SARICI. "CLL-247 Venetoclax Plus Ibrutinib As First-line Treatment in Patients With Chronic Lymphocytic Leukemia: Meta-Analysis of Randomised Controlled Trials," Society of Hematologic Oncology 2024 Annual Meeting, Texas, United States Of America, 2024

TANRIVERDİ, LOKMAN H. And SARICI, AHMET. "CLL-247 Venetoclax Plus Ibrutinib As First-line Treatment in Patients With Chronic Lymphocytic Leukemia: Meta-Analysis of Randomised Controlled Trials." Society of Hematologic Oncology 2024 Annual Meeting , Texas, United States Of America, pp.349, 2024

TANRIVERDİ, L. H. And SARICI, A. (2024) . "CLL-247 Venetoclax Plus Ibrutinib As First-line Treatment in Patients With Chronic Lymphocytic Leukemia: Meta-Analysis of Randomised Controlled Trials." Society of Hematologic Oncology 2024 Annual Meeting , Texas, United States Of America, p.349.

@conferencepaper{conferencepaper, author={LOKMAN HEKİM TANRIVERDİ And author={AHMET SARICI}, title={CLL-247 Venetoclax Plus Ibrutinib As First-line Treatment in Patients With Chronic Lymphocytic Leukemia: Meta-Analysis of Randomised Controlled Trials}, congress name={Society of Hematologic Oncology 2024 Annual Meeting}, city={Texas}, country={United States Of America}, year={2024}, pages={349} }